Patients with dilated cardiomyopathy（DCM）have higher incidence of heart lumen thrombosis and clinical thromboembolic events. Heart lumen thrombosis relates to many factors

including cardiac dilatation

the endocardial surface change

myocardial motion decreases

blood flow congestion

arrhythmia

blood high condensation state

etc. Now

the expert advice for adding anticoagulant therapy for patients with DCM is:left ventricular ejection fraction<30%

having a history of embolism performance

or mural thrombus formation in echocardiography. There were articles reported using aspirin

or by a combination of aspirin and hirudin drugs as conventional treatment for patients with cardiomegaly;some reported adding warfarin or new oral anticoagulants if cardiomegaly complicated with atrial fibrillation. This article reviewed the epidemiology

mechanism and prevention and cure for risk patients with DCM.